Paper
0
The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)
Authors
Anna Balarí,J. Núñez
María Casterá,Francisca Hernandez,Eva Domingo‐Domènech,Fátima Vicente,M. Moreno,Elena Amutio,Ana González-Rodríguez,Raúl Córdoba,Carmen Martı́nez,Samuel Romero,Mariana Bastos‐Oreiro,Antonia Izquierdo,Javier Briones,Richard Greil,María Espinosa,Araceli Ortíz‐Rubio,Irit Avivi,Raquel Campo,Pilar Gómez,Theodoros Vassilakopoulos,Sandra Bašić‐Kinda,Sotirios Papageorgiou,Víctor Concepción,Juan Blanco,Blanca Sánchez‐González,Izaskun Zeberio,Ramón Rubio,Eva Domingo‐Doménech,María Gil
+29 authors
,Izaskun CeberioJournal
Published
Nov 5, 2024
Show more
Save
Tip0
TipSave
Abstract
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.